Bulletin of Semashko National Research Institute of Public HealthBulletin of Semashko National Research Institute of Public Health2415-84102415-8429FSSBI «N.A. Semashko National Research Institute of Public Health»283010.69541/NRIPH.2024.03.003Научная статьяAn innovative approach to the management of a key geriatric pathology — dementiaYakushinMikhail A.yakushinma@mail.ruhttps://orcid.org/0000-0003-1198-1644KarpovaOlga V.dr/ovkarpova@yandex.ruhttps://orcid.org/0000-0002-9466-219XVorobevaAnna V.vorobievaanna2010@yandex.ruhttps://orcid.org/0000-0003-4609-5343PershinAndrey V.pershin-7@mail.ruhttps://orcid.org/0009-0004-2247-3244GabrielyanArtur R.gabrielyanarthur@gmail.comhttps://orcid.org/0000-0002-8895-8074KudrinAlexey P.noreply@nriph.ruhttps://orcid.org/0000-0001-6141-7350YakushinaTatiana I.yakutanya@mail.ruhttps://orcid.org/0000-0002-2245-309XN. A. Semashko National Research Institute of Public HealthMoscow State Regional UniversityResearch Institute for Healthcare Organization and Medical Management of Moscow Healthcare DepartmentMoscow Regional Research and Clinical Institute («MONIKI»)011020243162727052025Copyright © 2025,2025<p>The scientific team of the N.A.Semashko National Research Institute of Public Health conducted structuring and digitization of diagnostic criteria for the main forms of dementia, which made it possible to build a medical information system Diagnosis and Treatment of Cognitive Disorders (MIS) based on the 1C platform, designed to support medical decision-making in determining diagnosis and prescribing treatment to patients with cognitive disorders. Upon completion of clinical trials, it is planned to introduce MIS into the organization of the activities of memory impairment rooms.</p>cognitive disordersdementiamedical information systemdementia diagnosisdementia treatmentinnovative treatmentкогнитивные расстройствадеменциямедицинская информационная системадиагностика деменциилечение деменцииинновационное лечение1.Zudin A.B., Shchepin V.O. Global challenges for Russian healthcare. Bulletin of the N.A.Semashko National Research Institute of Public Health. [Bjulleten' Nacional'nogo nauchno-issledovatel'skogo instituta obshhestvennogo zdorov'ja imeni N.A.Semashko].2016;(5):41—45 (in Russian).2.3.Shchetkina A.L. Where are we on the way to fight dementia? A little bit about the experience — personal, Russian, foreign. The socio digger. [Socio digger]. 2022;5—6(18):72—75 (in Russian).4.5.Belousov Yu.B., Zyryanov S.K., Belousov D.Yu. et al. Clinical and economic aspects of Alzheimer's disease therapy in Russia. High-quality clinical practice. [Kachestvennaja klinicheskaja praktika]. 2009;(S1):3—28 (in Russian).6.7.Dementia. Fact sheet N362. World Alzheimer Report 2018. The state of the art of dementia research: New frontiers. London: ADI; 2018.8.9.O'connor D.W. Epidemiology of behavioral and psychological symptoms of dementia. J International psychogeriatric.2000;(1):41—45.10.11.Budson A.E., Kowall N.W. Handbook of Alzheimer’s disease and other dementias. Wiley- Blackwell; 2013.12.13.Koberskaya N.N. Alzheimer's disease: new diagnostic criteria and therapeutic aspects depending on the stage of the disease. Medical advice. [Medicinskij sovet]. 2017;(10):18—24 (in Russian).14.15.Gavrilova S.I. Dementia. Guide to geriatric psychiatry. M.: Pulse; 2014 (in Russian).16.17.Solomon P.R., Murphy C.A. Should we screen for Alzheimer’s disease? A review of the evidence for and against screening Alzheimer’s disease in primary care practice. J Geriatrics. 2005;60(11):26—31.18.19.Gauthier S. Clinical diagnosis and management of Alzheimer’s disease. Informa UK Ltd.; 2007.20.21.McKhann G.M., Knopman D.S., Chertkow H. et al. The diagnosis of dementia due to Alzheimer»s disease: recommendations from the National Institute on Aging-Alzheimer»s Association workgroups on diagnostic guidelines for Alzheimer»s disease. J Alzheimers Dement. 2011;7(3):263—269.22.23.Albert M.S., DeKosky S.T., Dickson D., et al. The diagnosis of mild cognitive impairment due to Alzheimer»s disease: recommendations from the National Institute on Aging-Alzheimer»s Association workgroups on diagnostic guidelines for Alzheimer»s disease. J Alzheimers Dement. 2011;7(3):270—279.24.25.Solodkov P.V. Differential diagnosis of dementia at the prehospital stage. Health and education in the 21st century [Zdorov'e i obrazovanie v XXI veke]. 2012;14(3):270 (in Russian).26.27.Frisoni G.B., Boccardi M., Barkhof F., et al. Strategic roadmap for an early diagnosis of Alzheimer»s disease based on biomarkers. J Lancet Neurol. 2017;16(8):661—676.28.29.Jennifer S.L., Elizabeth O'Connor, Rebecca C.R., et al. Screening for Cognitive Impairment in Older Adults: An Evidence Update for the U.S.Preventive Services Task Force. J Agency for Healthcare Research and Quality. 2013;(11):14—19.30.31.Knop man D.S., De Kosky S.T., Cummings J.L., et al. Practice p arameter: diagnosis of dementia (an evidence-based review). Rep ort of the Quality Standards Subcommittee of the American Academy of Neurology. J Neurology. 2001;56(9):1143—1153.32.33.Breton A., Casey D., Arnaoutoglou N.A. Cognitive tests for the detection of mild cognitive imp airment (MCI), the p rodromal stage of dementia: Meta-analysis of diagnostic accuracy studies. Int J Geriatr Psychiatry. 2019;34(2):233—242.34.35.Belleville S., Fouquet C., Hudon C. et al. Neurop sychological Measures that Predict Progression from Mild Cognitive Imp airment to Alzheimer»s typ e dementia in Older Adults: a Systematic Review and Meta-Analysis. J Neurop sychol Rev. 2017;27:328—353.36.37.Gutorova D.A., Vasenina E.E., Levin O.S. Screening of cognitive impairment in the elderly and senile using the 3-CT scale. Journal of Neurology and Psychiatry named after S.S.Korsakov [Zhurnal nevrologii i psihiatrii im. S.S.Korsakova]. 2016;116(6):35—40 (in Russian).38.39.Levin O.S. Algorithms for the diagnosis and treatment of dementia. M.: MEDpress-inform.; 2017. (in Russian).40.41.Yakhno N.N., Preobrazhenskaya I.S., Zakharov V.V. and others. The prevalence of cognitive impairment in neurological diseases (analysis of the work of a specialized outpatient appointment). Neurology, neuropsychiatry, psychosomatic[Nevrologija, nejropsihiatrija, psihosomatika]. 2012;2:30—35 (in Russian).42.43.Vasenina E.E., Levin O.S., Sonin A.G. Current trends in the epidemiology of dementia and the management of patients with cognitive impairment. Journal of Neurology and Psychiatry named after S.S.Korsakov. [Zhurnal nevrologii i psihiatrii im. S.S.Korsakova]. 2017;117(6):87—95 (in Russian).44.45.Beynon R., Sterne J.A., Wilcock G., et al. Is MRI better than CT for detecting a vascular comp onent to dementia? A systematic review and meta-analysis. J BMC Neurol. 2012;12(33):1—10.46.47.Health Quality Ontario. The app rop riate use of neuroimaging in the diagnostic work-up of dementia: an evidence-based analysis. J Ont Health Technol Assess Ser. 2014;14(1): 1—64.48.49.Ashburner J. Unified segmentation. J Neuroimage. 2005;26(3): 839—851.50.51.Baykov D.E., Gizatullin R.R., Shaimardanova K.R. and others. Determining the size of brain structures using voxel morphometry. Ural Medical Journal. [Ural'skij medicinskij zhurnal]. 2017;9(153): 17—21 (in Russian).52.53.Kesler A., et al. Retinal thickness in patients with mild cognitive impairment and Alzheimer’s disease. J Clin. Neurol. Neurosurg. 2011;(7):523—526.54.55.Erichev V.P., Panyushkina L.A., Fomin A.V. Optical coherence tomography of the retina and optic nerve in the diagnosis of Alzheimer's disease. Glaucoma. [Glaukoma]. 2013;(1):5—10 (in Russian).56.57.Hort J., O'Brien J.T., Gainotti G. et al. EFNS guidelines for the diagnosis and management of Alzheimer`s Disease. Eur J Neurol. 2010;17(10):1236—1248.58.59.Forlenza O.V., Radanovic M., Talib L.L. Cerebrosp inal fluid biomarkers in Alzheimer’s disease: Diagnostic accuracy and p rediction of dementia. J Alzheimer’s & Dementia. 2015;(1):455—463.60.61.Komatsu J., Samuraki M., Nakajima K., et al. 123I-MIBG myocardial scintigrap hy for the diagnosis of DLB: a multicentre 3-year follow-up study. J Neurol Neurosurg Psychiatry. 2018;89(11):1167—1173.62.63.Thomas A.J., Taylor J.P., McKeith I. et al. Revision of assessment toolkits for improving the diagnosis of Lewy body dementia: The DIAMOND Lewy study. J Geriatr Psychiatry. 2018;33(10):1293—1304.64.65.Shore J., Johnson R. Axiomatic derivation of the principle of maximum entropy and the principle of minimum cross-entropy. J IEEE Transactions on information theory. 1980;26(1):26—37.66.67.Tolibov D.S., Rakhimbayeva G.S. Approbation of a new diagnostic complex of biomarkers for the differential diagnosis of Alzheimer's disease. Medical news. [Medicinskie Novosti].2016;(4):63—65 (in Russian).68.69.Vlasenko A.G., Illarioshkin S.N. Neuroimaging in the differential diagnosis of dementia. Journal of Neurology and Psychiatry named after S.S.Korsakov. [Zhurnal nevrologii i psihiatrii im. S.S.Korsakova]. 2012;112(6):86—90 (in Russian).70.71.Illarioshkin S.N., Vlassenko A.G. Neurovisualization in the differential diagnosis of dementia. J Zhurnal nevrologii i psikhiatrii imeni S.S.Korsakova. 2012;(6):86—90.72.73.Gómez-Tortosa E., Gonzalo I., Fanjul S., et al. Yèbenes J.G., del Ser T. Cerebrospinal fluid markers in dementia with Lewy bodies compared with Alzheimer disease. J Archives of Neurology.2003;60(9):1218—1222.74.75.Mollenhauer B., Esselmann H., Trenkwalder C., et al. CSF amyloid-β peptides in neuropathologically diagnosed dementia with Lewy bodies and Alzheimer’s disease. J. Alzheimers Dis. 2011;24(2):383—391.76.77.Bibl M., Mollenhauer B., Lewczuk P., et al. Cerebrospinal fluid tau, p-tau 181 and amyloid-β38/40/42 in frontotemporal dementias and primary progressive aphasias. J Dement. Geriatr. Cogn. Disord. 2011;31(1):37— 44.78.79.Bibl M., Esselmann H., Lewczuk P., et al. Combined Analysis of CSF Tau, Aβ42, Aβ1—42% and Aβ1—40% in Alzheimer’s Disease, Dementia with Lewy Bodies and Parkinson’s Disease Dementia. J Alzheimers Dis. 2010;(24):761—765.80.81.Otto M., Esselmann H., Schulz-Schaeffer W., et al. Decreased β-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J Neurology. 2000;54(5):1099—1102.82.83.Jack C.R. Jr., Bennett D.A., Blennow K., et al. Toward a Biological Definition of Alzheimer’s Disease. J Alzheimers Dement. 2018;14(4):535—562.84.85.Roman G.C., Tatemichi T.K., Erkinjuntti T. et al. Vascular dementia: diagnostic criteria for research studies: rep ort of the NINDS-AIREN International Work Group . J Neurology.1993;(43):250—260.86.87.Sachdev P., Kalaria R., O’Brien J. et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. J Alzheimer disease and associated disorders. 2014;28(3):206—218.88.89.Atri A. The Alzheimer’s disease clinical spectrum: diagnosis and management. J Med. Clin. North Am. 2019;(103):263—293.90.91.Levin O.S. Diagnosis and treatment of dementia in clinical practice. M.: MEDpress-inform; 2010 (in Russian).92.93.McKeith I.G., Boeve B.F., Dickson D.W. et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. J Neurology.2017;(89):1—13.94.95.Mesulam M.M., Wieneke C., Thompson C., et al. Quantitative classification of primary progressive aphasia at early and mild impairment stages. J Brain. 2012;(135):1537—1553.96.97.Gorno-Tempini M.L., Hillis A., Weintraub S, et al. Classification of primary progressive aphasia and its variants. J Neurology. 2011;(76):1006—1014.98.99.Gaidukov A.I., Mikheev V.V., Poluektov S.V. Regional laboratory information system based on 1C: Medicine. Clinical laboratory. Polyclinic. [Poliklinika]. 2018;4(1):20-23 (in Russian).